Does Wegovy Damage Your Liver — or Could It Actually Help?

Why people worry about Wegovy and the liver (and what the evidence actually says

It is a question our prescribers hear most weeks: 'I've read something about Wegovy and the liver) should I be worried?' The worry is understandable. GLP-1 medicines are relatively new in weight management, the internet surfaces alarm quickly, and the liver is not an organ anyone wants to experiment with. The reassuring reality is that the clinical evidence does not support the idea that Wegovy damages the liver, and understanding why that conclusion holds up is worth a moment of your time.

Semaglutide has been studied in large randomised trials involving thousands of participants. Across those trials (including STEP 1, published in the New England Journal of Medicine) liver-related adverse events were not a signal that emerged. Post-marketing surveillance, which continues because Wegovy carries a Black Triangle (▼) status requiring additional MHRA monitoring, has not identified liver damage as a safety concern. The NHS's own medicines information for semaglutide reflects this: liver injury does not appear among the listed side effects.

Where elevated liver enzymes are noticed during treatment, clinicians generally consider whether the readings reflect the underlying condition improving as liver fat reduces, rather than new harm being done. That distinction matters and is one reason any abnormal result warrants a conversation with your GP or prescriber rather than an immediate assumption that the medicine is responsible. Anyone wanting a fuller breakdown of whether semaglutide causes liver damage will find the evidence reviewed in detail on that dedicated page.

Wegovy's relationship with fatty liver disease is moving in a striking direction

The most significant recent development is not a warning, it is a new indication. On 3 July 2026, the MHRA conditionally approved semaglutide (Wegovy) to treat MASH (metabolic dysfunction-associated steatohepatitis) in adults with moderate-to-advanced liver fibrosis, as confirmed by the gov.uk announcement. MASH is a serious progressive form of fatty liver disease; until this approval, there was no licensed medicine for it in the UK.

This approval was supported by trial data showing that semaglutide reduced liver inflammation and slowed fibrosis progression in a meaningful proportion of participants. The medicine does not work for everyone with liver disease, and conditional approval means ongoing data collection is required. But this is the opposite trajectory from the worry that Wegovy harms the liver.

If your concern is specifically about MASH or non-alcoholic fatty liver disease, that conversation needs to involve a hepatologist or specialist alongside any prescriber. Wegovy is licensed for weight management; the MASH indication is a separate clinical pathway. What someone with liver disease should or should not take is genuinely individual and falls outside any service's power to prescribe without specialist input.

Pre-existing liver conditions: what to tell your prescriber before you start

The picture changes if you have a known liver condition. Severe hepatic impairment can affect how medicines are processed in the body, and while semaglutide's pharmacokinetics are not primarily liver-dependent, any prescriber should know your liver history before treatment begins. This is not a contraindication in most cases, but it is information that shapes the clinical decision.

A reputable prescribing service will ask about liver conditions directly during the consultation. At nume, the clinical team personally reviews every consultation; nothing is waved through automatically. If your liver condition is actively managed by a specialist, it is worth flagging that explicitly and, where possible, sharing recent blood results. You can explore what our consultation covers on the about us page.

One practical note: if you are taking medicines for a liver condition, some of those may interact with GLP-1 treatments in ways worth discussing. The slowing of gastric emptying that semaglutide produces can alter how other oral medicines are absorbed. Your prescriber and, where relevant, your hepatologist should both be in the loop before you start.

How to use this information when deciding whether to proceed

If you arrived here worried that Wegovy would harm your liver, the honest answer is: the evidence does not support that concern for people with normal or mildly affected liver function. For people with significant liver disease, the answer is more nuanced and belongs with specialists, not with a search result.

The broader Wegovy overview covers how the medicine works, its licensed eligibility criteria, and what private treatment involves. Questions about cost are addressed on the Wegovy prices page. For related questions about semaglutide and the liver specifically, our clinical team has also addressed whether semaglutide causes liver damage and how Wegovy affects the liver in more depth.

If you are clinically suitable, starting a free consultation through our weight-loss treatments page is the right next step. A prescriber will assess your full health picture, including any liver concerns, before any prescription is issued. That assessment is what makes the difference between a well-reasoned clinical decision and a guess.